EUCTR2010-019253-18-PL进行中（未招募）1 期
A phase II, open-label, multicentre study to evaluate the safety and immunogenicity of GSK Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine as a booster dose in children aged 12 to 18 months, previously primed with the same vaccine in the primary vaccination study DTPa-HBV-IPV=Hib-MenC-TT-002 (112157). - DTPA-HBV-IPV=HIB-MENC-TT-004 BST: 002
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subjects who the investigator believes that parent(s)/ Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
- •- Subjects who have completed the full three-dose primary vaccination course according to their group allocation in the primary study DTPa-HBV-IPV=Hib-MenC-TT-002 (112157).
- •- A male or female between, and including, 12 and 18 months of age at the time of booster vaccination.
- •- Written informed consent obtained from the parent(s)/LAR(s) of the subject.
- •- Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Child in care.
- •- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the dose of study vaccine, or planned use during the study period.
- •- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccination. For corticosteroids, this will mean prednisone =0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
- •- Planned administration/administration of immunoglobulins and/or any blood products within three months before the booster dose, or during the study period.
- •- Planned administration/administration of any vaccine not foreseen by the study protocol during the period starting 30 days before and ending 30 days after the booster dose.
- •- Participation in another clinical study since the primary study DTPa-HBV-IPV/Hib-MenC-TT-002 in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- •- Evidence of previous diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Hib, pneumococcal and MenC vaccination or disease since the conclusion visit of study DTPa-HBV-IPV/Hib-MenC-TT-002 (Pneumococcal vaccination is allowed in the MnC-CRM Group).
- •- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
- •- The following adverse event having occurred after previous administration of DTP vaccine:
- •- Encephalopathy defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination and generally consisting of major alterations in consciousness, unresponsiveness, generalized or focal seizures that persist more than a few hours, with failure to recover within 24 hours.
- •- Temperature of = 40.5°C (rectal temperature) within 48 hours of vaccination, not due to another identifiable cause.
- •- Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
- •- Persistent, inconsolable crying occurring within 48 hours of vaccination and lasting = 3 hours.
- •- Seizures with or without fever occurring within 3 days of vaccination.
- •The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met:
- •- Acute disease and/or fever at the time of enrolment.
- •- Fever is defined as temperature = 37.5°C on oral, axillary or tympanic setting, or = 38.0°C on rectal setting. The preferred route for recording temperature in this study will be axillary.
- •- Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
研究者
相似试验
进行中（未招募）
不适用
A phase II, open-label, multicentre study to evaluate the pharmacodynamic profile, the efficacy and the safety of a 6-month sustained-release formulation of triptorelin in patients with prostate cancer - Not applicableEUCTR2006-007055-41-LTBeaufour Ipsen Pharma - 24, rue Erlanger 75016 Paris FRANCE12
尚未招募
Unknown
A phase 2, multi-center, open-label study to evaluate the safety, tolerability and efficacy of combination regimen of GI-101A and SL-T10 in patients with metastatic castration-resistant prostate cancer (mCRPC)NeoplasmsKCT0008799Asan Medical Center72
进行中（未招募）
1 期
An open-label study to assess safety and tolerability of NurOwn® in participants with early stage of Alzheimer's DiseaseAlzheimer's DiseaseEUCTR2020-002872-11-NLBrainstorm Cell Therapeutics, Ltd.40
招募中
2 期
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinomaadrenocortical carcinoma2024-517205-82-00Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy24
招募中
1 期
The study is a Phase 2, open-label, multicenter study to determine the efficacy and safety of Luspatercept (ACE-536) in adults with congenital dyserythropoietic anemia type II (CDA II).Congenital Dyserythropoietic Anemia type II (CDAII)MedDRA version: 21.1Level: PTClassification code 10081457Term: Congenital dyserythropoietic anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-005736-30-ITFOndazione per la Ricerca sulle ANemie ed EMoglobinopatie in ItaliA - For Anemia40